Background The American Academy of Pediatrics recommends a permissive hypoxaemic target for an oxygen saturation of 90% for children with bronchiolitis, which is consistent with the WHO recommendations for targets in children with lower respiratory tract infections. No evidence exists to support this threshold. We aimed to assess whether the 90% or higher target for management of oxygen supplementation was equivalent to a normoxic 94% or higher target for infants admitted to hospital with viral bronchiolitis.
Introduction
Oxygen saturation targets standardise clinical care in patients with acute disease, aiming to maintain tissue oxygenation and improve clinical outcomes. No randomised clinical trial has assessed oxygen saturation targets in management of patients with acute lower respiratory infection (LRTI). 1 The most common acute LRTI in early life is acute viral bronchiolitis, which causes about 128 000 hospital admissions each year in the USA at an estimated cost of US$1·73 billion. 2 Applying standard unit cost estimates to annual rates in the UK reveals that the annual cost of paediatric bronchiolitis to NHS England would be about £83·8 million. This fi gure is based on 37 200 cases of paediatric bronchiolitis per year 3 with an average cost per case of £2254. 4 In 2006, two evidence-based guidelines for the management of bronchiolitis included contrasting recommendations for oxygen saturation targets. The UK SIGN guideline (SIGN 91 5 ) recommended a normoxic pulse oxygen saturation (SpO₂) target (≥94%), whereas the American Academy of Pediatrics (AAP) 6 recommended a permissive hypoxaemic SpO₂ target (≥90%; reiterated 2014 7 ). The AAP's advice is consistent with WHO's recommended SpO₂ target of 90% and higher in infants with LRTI. However, WHO's recommendation is considered pragmatic advice for best use of scarce oxygen availability in low-resource settings, 8 and neither AAP or WHO targets have been tested in a randomised controlled trial.
Despite AAP's guidance, recommended SpO₂ targets for infants with bronchiolitis continue to vary between national guideline portals for the USA, 9 Europe, 10 and Australasia. This inconsistency might show clinical hesitance to adopt a lower SpO₂ target for infants than is currently recommended for older children with pneumonia (≤92%) 11 and asthma (<94%), 12 or a reticence to use hypoxaemic targets provided by expert opinion when similar recommendations have been associated with unanticipated adverse events once tested in a randomised controlled trial. 13 We aimed to assess whether a target oxygen saturation of 90% or higher would be equivalent to 94% or higher for resolution of illness in acute viral bronchiolitis. To do this we assessed time to resolution of cough, which is associated with airway infl ammation and might be infl uenced by hypoxia. 14, 15 Cough is a ubiquitous symptom in bronchiolitis consistently identifi ed by parents and has a duration well documented in many trials. 16 
Methods

Study design and participants
We did a parallel-group, randomised, controlled, equivalence trial at eight paediatric hospitals in the UK during two 6-month winter bronchiolitis seasons (fi ve centres in season one with three additional centres added in season two; appendix p 2). The protocol is available online. A health economic cost-eff ectiveness analysis was also done and is reported separately.
Infants aged between 6 weeks and 12 months of age (corrected for prematurity) who presented to a participating hospital emergency department or acute assessment area, either by general practice referral or spontaneous attendance, were assessed by acute care medical staff for potential trial recruitment. To be eligible for recruitment, infants had to have a clinical diagnosis of bronchiolitis (consistent with SIGN 91 Bronchiolitis 5 ) made by receiving acute medical staff and required admission to hospital for supportive care. The clinical decision to admit an infant with bronchiolitis prompted randomisation to the study. We excluded infants who: were preterm (<37 weeks' gestation) and had received oxygen therapy in the past 4 weeks; had cyanotic or haemodynamically signifi cant heart disease; had cystic fi brosis or interstitial lung disease; had documented immune function defi cit; were directly admitted to a high dependency or intensive care area; or were previously randomised.
South East Scotland Research Ethics Committee 3 provided multicentre UK ethical approval. Written, informed consent was obtained from the parent or legal guardian.
Randomisation and masking
We randomly allocated (1:1) infants to a standard pulse saturation oximeter or a modifi ed pulse saturation oximeter. Randomisation was by a central internetbased secure password-protected computer. The random allocation sequence was generated by computer programme at the Edinburgh Clinical Trials Unit, UK. Randomisation was by blocks of varying length (four and six) without stratifi cation. Infants were enrolled by clinicians and research or specialist nurses in the hospital emergency department or acute assessment area, and group allocation was concealed until defi nite enrolment. Clinicians (mostly nursing staff ) attached either a standard or modifi ed pulse oximeter according to the computer-generated randomisation code. Oximeters were attached with an interval of at least 1 min after removal of the hospital oximeter and within 4 h of arrival at hospital, and most typically at the point of preparing to transfer from hospital emergency department or acute assessment area to a hospital ward. Monitors were identical in appearance (except for study number). The average diff erence between displayed standard and modifi ed oximeter values was 2% SpO₂ (appendix p 3). To reduce risk of unmasking, oximeters had new study numbers allocated for season two. All study staff involved in day-to-day running of the trial, hospital staff , and parents were masked to study intervention, as were those assessing outcomes. The mask was not broken for any infant during the study.
For the protocol see http://www. clinicaltrials.ed.ac.uk/LinkClick.as px?fi leticket=YB_4elxWL2Q%3d &tabid=66
Research in context
Evidence before this study We searched PubMed and Scopus for clinical trials published in English with the terms "oxygen", "oximetry", "saturation", "bronchiolitis", "pneumonia", and "lower respiratory tract infection" in humans (all ages) up to Oct 26, 2014 . We could identify no randomised controlled trials. A Cochrane systematic review of oxygen therapy for lower respiratory tract infection in children aged 3 months to 15 years identifi ed no randomised controlled trials up to April 30, 2008 . An observational study in Papua New Guinea (Duke et al, 2008) identifi ed that deaths from lower respiratory tract infection were reduced in children provided with supplemental oxygen for SpO₂ lower than 90% when compared with historical controls.
Added value of this study
To our knowledge, this is the fi rst randomised controlled trial of oxygen saturation targets of children with bronchiolitis or any lower respiratory tract infection. Providing supplemental oxygen to a saturation target of 90% in infants with bronchiolitis was safe and clinically eff ective. There was some evidence of better outcomes in infants managed to a 90% SpO₂ target.
Implications of all the available evidence
Further trials are warranted of older children with lower respiratory infection, and our results suggest that the current 90% SpO₂ threshold might be open to investigation, especially in lowresource settings with little availability of supplemental oxygen.
Procedures
Standard pulse oximeters (Rad 8 with LNC 10 patient cable, Masimo, CA, USA) measured and displayed oxygen saturation in the typical way. Identical-looking modifi ed oximeters measured arterial oxygen saturation as per standard oximeters, but manufacturer-altered internal algorithms provided a non-standard displayfor the range 85-100% the algorithm skewed the displayed values so that at a measured value of 90% the monitor would display 94%, with smoothed displayed values above and below this point (appendix). Staff were instructed to provide supplemental oxygen to infants with an SpO₂ of lower than 94%. Therefore, infants with modifi ed oximeters would not be given supplemental oxygen at a displayed 94% oxygen saturation, but actual 90% oxygen saturation. Pilot work for the trial showed very high variability of SpO₂ improvement in bronchiolitis during recovery 17 and this information was provided to staff during study education. Study staff followed up participants and parents or carers during the hospital stay and also by structured telephone questionnaire at 7, 14, and 28 days, and 6 months after randomisation to assess outcomes. To maximise accurate recall, we provided parents with study cards at discharge to remind them of outcomes that would be assessed at each follow-up. Every eff ort was made to minimise dropout and non-compliance. We measured parental anxiety with the anxiety subscale of The Hospital Anxiety and Depression Score (HADS). 18 Viral identifi cation was done with routine PCR or near patient testing of nasal secretions.
Discharge from hospital was at the discretion of the paediatrician responsible for care; however, we asked that study infants be considered eligible and fi t for discharge from hospital once they had attained stable SpO₂ of 94% or higher continuously for 4 h (including a period of sleep) and were feeding orally at 75% or more of their expected intake of milk daily. In all other aspects, management was according to local paediatric care.
Outcomes
The primary outcome for equivalence was time to resolution of cough. Evidence of limits of equivalence could not be determined from published data and so we used expert opinion from a survey of ten general paediatricians from Royal Hospital for Sick Children, Edinburgh, UK, as plus or minus 2 days (appendix). Cough resolution as determined by parents was noted during the routine telephone contacts. Parents were reminded at each contact of the information they would be asked to provide at the next call and requested to note the date of cough resolution on their study card. Subgroup analyses were prespecifi ed for length of illness before randomisation (0-3 days vs 4 or more), use of antibiotics (any vs none), and household smoking (any vs none).
Further prespecifi ed outcomes assessed for equivalence were time to feed adequately (≥75% usual) with limits of equivalence of plus or minus 4 h; time to a parental perception of back to normal with the limits of equivalence plus or minus 2 days; SpO₂ measured at 28 days with limits of equivalence of plus or minus 1%. Subgroup analyses were prespecifi ed for time to fi t for discharge and actual discharge by in-hospital oxygen requirement. After a review by the data monitoring committee of data from season one for SpO₂ at 28 days, equivalence was identifi ed with no safety concerns and further measurement was stopped to help with study logistics.
A predetermined statistical analysis plan included an assessment of diff erences between the groups for the time from randomisation until fi t for discharge and actual discharge for all infants admitted with bronchiolitis; proportion of infants with health-care reattendance (primary care, emergency department, readmission; parental phone calls); child well enough to attend to childcare (parental phone calls) for days 0-7, 7-14, and 14-28; and diff erence in parental anxiety score at 7, 14, and 28 days and 6 month follow-up. A subgroup analysis was made of time from randomisation to fi t for discharge and actual discharge from hospital in those infants with an oxygen requirement during their stay. We did a full economic analysis alongside the trial, to calculate the incremental cost and eff ectiveness of the 90% compared with the 94% oxygen saturation discharge procedure in terms of health, social care, and societal costs, as well as the clinical and quality-of-life outcome measures. The analysis was undertaken from the UK NHS perspective, with a sensitivity analysis considering societal costs from the parents' perspective.
Statistical analysis
Sample size was established based on the primary outcome of time to resolution of cough after randomisation. An estimate of 544 participants needed was made by assumption that there would be no diff erence between the treatment groups, with a common SD of 8·3 days from Plint and colleagues 19 The SD of 8·3 was calculated by dividing the IQR by 1·35. 19, 20 This used a two-sided test (overall α of 0·05), with power of 80%, and limits of equivalence of 2 days (ie, the diff erence between the two groups could be up to 2 days in either direction). To allow for skewness in the outcome measure, drop-outs, and non-compliance, we aimed to recruit 600 infants. There were no preplanned stopping rules.
The primary analysis was done by intention to treat, in which we analysed all randomly assigned infants by allocated treatment, irrespective of treatment received. However, for equivalence outcomes, we also did per-protocol analyses of infants who received a pulse oximeter analysed by treatment received; fi rm conclusions were only declared when intention-to-treat and per-protocol analyses agreed. Safety analyses were done by intention to treat. The primary analysis was unadjusted. All statistical tests were two-sided with 5% signifi cance. For all outcomes, we used a complete case analysis, but for some equivalence analyses (time to cough resolution and time back to normal), imputation was used for the primary analysis, as follows. If a date of event was known, it was used. If it was known that the event occurred, but the precise date was not known, a value was chosen between the date that the event was last known to not be present and the date of the follow-up when it was present. Then a value was chosen at random from patients in the same treatment group whose cough stopped in a similar timeframe. If it was known that the event had not occurred by 6 months, then the event date was taken at random from a uniform distribution capped at 200 days. 21 If it was known that the event had not occurred by the last follow-up done, but the patient was not followed to 6 months, then a random value was chosen from a uniform distribution starting at the last known follow-up point until 200 days. This process was repeated 100 times, and the analysis done on each dataset. The mean values for the estimate of the median, and the estimates of the CI limits were used.
For equivalence outcomes, the diff erence in medians (and 95% CIs) between treatments was estimated using a non-parametric method. 22 The treatments were considered equivalent if the 95% CI lay within prespecifi ed equivalence limits. For time to re-establish adequate feeding, no imputations were necessary. For oxygen saturation, we estimated the diff erence in mean oxygen saturation by an independent sample t test.
We used logistic regression for binary outcomes, poisson regression for counts, normal linear models for continuous outcomes, and ANCOVA, adjusting for baseline score where relevant data were recorded.
We used SAS version 9.3 for Windows for all analyses. The data monitoring committee were all based in the UK. They worked to a prespecifi ed data monitoring committee charter and convened a meeting on three occasions to review unblinded data. A data monitoring committee met at the end of season one and recommended the study continue as planned. This trial is registered with ISRCTN, number ISRCTN28405428.
Role of the funding source
The funder was not involved in the collection, analysis, interpretation of data, writing of the report or the decision to publish. Masimo provided altered algorithms for study oximeters, but was not involved in study design or collection, analysis, interpretation of data, writing of the report, or the decision to publish. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Between Oct 3, and March 30, 2012, and Oct 1, and March 29, 2013, we recruited 615 infants of median age 21·3 weeks (IQR 11·7-31·6). We randomly assigned 308 infants to be monitored with standard oximeter (standard group) and 307 to be monitored with the modifi ed oximeters that displayed SpO₂ 90% as SpO₂ 94% (modifi ed group; fi gure 1). The trial steering committee decided to continue to the end of season two, which is why the sample size is 615 people instead of 600 as planned. There were protocol deviations relating to the pulse oximeters (attached late, removed early, or never attached) on 26 occasions in 26 infants in the standard group and 31 occasions in 30 infants in the modifi ed group. Seven infants were incorrectly attached to a standard oximeter when randomised to modifi ed care, and one given a modifi ed oximeter when randomised to standard care. These infants were analysed in the group to which they were allocated in the ITT analysis, but to that received in the per protocol analysis. Six standard and nine modifi ed pulse oximeters were never attached.
Baseline characteristics were similar between the two groups, apart from the modifi ed group had fewer boys and more infants were preterm (table 1). 194 (70%) of 278 infants in the standard group and 213 (76%) of 279 in the modifi ed group tested positive for respiratory syncytial virus by PCR or near patient testing.
Median time to cough resolution was 15·0 days in both standard and modifi ed groups with a median diff erence of 1·0 day (95% CI -1 to 2; table 2). This interval and 95% CI falls within the prespecifi ed equivalence limits of plus and minus 2 days. Both the prespecifi ed complete-case analysis for the ITT population and per-protocol analysis (n=297 for standard group; n=279 for modifi ed group) had a median diff erence of 0 days (95% CI -1 to 2; table 2, appendix p 4). Because all intervals fell within the prespecifi ed equivalence limits, we consider the groups equivalent for the primary outcome. No diff erences of note were found in the prespecifi ed subgroup analyses for time to cough resolution (appendix p4).
Infants returned to adequate feeding 2·7 h sooner (median) in the modifi ed group, with the 95% CI (-0·3 to 7) falling outside the prespecifi ed limits of plus or minus 4 h. Similarly, infants in the modifi ed group were considered back to normal 1 day sooner by parents (table 2) with the 95% CI of 0 to 3 also falling outside prespecifi ed limits (plus and minus 2 days). These fi ndings were not anticipated.
We did a post-hoc analysis for the diff erence between time-to-event outcomes using Cox proportional hazards regression to estimate the treatment eff ect (HRs given for modifi ed vs standard). Time to return to adequate feeding gave a HR of 1·22 (95% CI 1·04-1·44, p=0·015), and for time back to normal a HR of 1·19 (95% CI 1·00-1·41, p=0·043). Thus, we have not proved equivalence for these outcomes and suggest that the modifi ed group might have benefi ted more.
At day 28, SpO₂ values (median 99%; IQR 97-100) did not signifi cantly diff er between the groups, with a mean diff erence of 0·111 (95% CI -0·35 to 0·57, p=0·64; prespecifi ed limits of agreement plus or minus 1%). Supplemental oxygen was provided to 223 (73%) of 305 of infants in the standard group and 169 (56%) of 304 in the modifi ed group. Oxygen was provided for signifi cantly longer in the standard group than the modifi ed group (table 2) . Infants were also fi t for discharge and were discharged signifi cantly sooner in the modifi ed group (table 2) , with benefi t to those who required supplemental oxygen (fi gure 2).
Serious adverse events and adverse events were recorded up to 28 days after randomisation. We recorded 35 serious adverse events in 32 infants in the standard care group and 25 serious adverse events in 24 infants in the modifi ed care group. In the 28 days after randomisation 173 adverse events were recorded in 144 infants: 89 adverse events in 75 infants in the standard care group and 84 adverse events in 69 infants in the modifi ed care group. No important diff erences were noted between group for type of event (respiratory, gastrointestinal) or severity (appendix p 5).
The standard care group had eight episodes of high-dependency unit admission (in eight infants), 26 readmissions to hospital (in 23 infants), and one prolonged hospital stay. The modifi ed care group had 13 episodes of high-dependency unit admission (in 12 infants) and 12 readmissions to hospital (in 12 infants). Time to readmission to hospital did not signifi cantly diff er between groups; median diff erence was 0·9 days (95% CI 0·4-2·0, p=0·8410). The number of health-care contacts (primary, emergency, or hospital) up to 28 days was similar (table 3) .
Resource use of therapies in hospital other than oxygen was similar in the two groups. A cost analysis from a UK National Health Service (NHS) perspective showed a $496 (£290) mean cost saving per patient associated with the modifi ed oximeters over the study period (appendix). This was a statistically insignifi cant result; however, exploring the individual components of the total NHS cost, the hospital inpatient stay variable was signifi cantly higher in the standard group (£1055 compared to £886, p<0·05). Data are n (%), n/N (%), or median (IQR). On arrival relates to arrival at the emergency department. Data were missing for the following numbers of patients (standard group, modifi ed): primary care attendances (7, 4) , heart rate (3, 4) , respiratory rate (9, 5), length of illness (3, 5) , and SpO₂ (4, 4) . SpO₂=pulse oxygen saturation. Early discharge did not result in parents in the modifi ed group having greater levels of anxiety at 7, 14, or 28 days (appendix). Lead carers discharged home sooner in the modifi ed group actually lost fewer hours to usual activities than did those in the standard group discharged later, with a median gain of 13·5 h by 7 days, 17·3 h by 14 days and 16·1 h by 28 days (appendix p 7). Only few children were attending child-care at the time of admission, with similar times to return to child-care from randomisation to 28 days (appendix p 7).
Discussion
In children with acute viral bronchiolitis, the time taken for symptoms to resolve was the same whether they were managed to a target oxygen saturation of 90% or 94%. As might be expected, when managed to a 90% SpO₂ target, fewer infants needed oxygen, those that did needed it for a shorter duration, and the infants were discharged home sooner. Somewhat unexpectedly, we found that infants managed to the lower target of 90% might regain satisfactory feeding and be back to normal sooner and have fewer readmissions to hospital. The return to adequate oral feeding a median diff erence of 2·7 h sooner in the modifi ed group might simply show a more assertive approach to oral feeding by staff when infants were considered to have oxygen saturation in the normal range. However, feeding diffi culties could also be prolonged in infants (obligate nasal breathers) by the drying of nasal secretions by oxygen gases and the increased resistance to nasal airfl ow created by a nasal cannula to deliver oxygen. Parents of infants in the modifi ed group considered them to return to normal health 1 day sooner than did parents of infants in the standard group. Although this fi nding might represent a time from discharge eff ect, it could also be consistent with a previous report of better outcomes in children with bronchiolitis when exposed to fewer interventions. 23 Infants were considered by parents to be back to normal health sooner than parents reported complete cough resolution, presumably denoting that resolving cough is one component of being back to normal health but does not defi ne it. We did not anticipate that fewer readmissions would occur in the modifi ed group because we considered these infants would be discharged sooner in the course of their illness and therefore more likely to be readmitted. The 5% absolute reduction in readmissions for infants at day 28 in the modifi ed group (14 fewer admissions) could be considered a clinically important diff erence. The reasons for diff erential readmission rates can only be speculative, but those with a longer stay in hospital might have been at greater risk of nosocomial infection or possible oxygen toxicity leading to readmission.
The strength of this study is that we provide evidencebased target oxygen saturation for the management of acute bronchiolitis. Guideline-recommended expert opinion for permissive hypoxaemic targets has previously been associated with poor outcomes when tested in randomised trials, prompting the recommended saturation target to be raised. 13 However, some limitations should be noted. We did no assessment of neurocognitive outcomes. Concerns were raised after following the AAP recommendation for permissive hypoxemia that the practice might aff ect neurocognition. 24 However mild hypoxaemia seems to 25 Infants recovering from bronchiolitis supplemented to a stable SpO₂ of 90% would have less hypoxia over a shorter timescale than that typically seen in those with obstructive sleep apnoea, and so the risk to infants in our study seem very low or absent. Another limitation is that we did not assess safe oxygen saturation for the management of children in a primary care or emergency department setting; however, the protocol did incorporate a pragmatic brief observation period (4 h) with the purpose that this trial could provide supportive evidence for a future study of safe targets for SpO₂ in bronchiolitis in hospital emergency department or acute assessment area and primary care. Recent studies suggest that a more fl exible approach to SpO₂ in the assessment of bronchiolitis in emergency departments should be pursued. 26 Furthermore, in designing a trial to study the eff ects of oxygen saturation targets in emergency admissions to hospital wards, we had to meet the challenges of high levels of recruitment in an acute setting and satisfactory masking. Our pilot work 27 revealed that 48% of infants admitted with bronchiolitis have satisfactory oxygen saturation on arrival at the emergency department with desaturation after admission. The logistics of recruitment, randomisation, and maintained masking of infants who were admitted and subsequently desaturated persuaded us that observation of the whole population admitted to hospital would provide the best opportunity to study this proposed policy change. The trial design reported here therefore has the eff ect that the intervention is limited to those infants in both groups of the trial who were admitted to hospital and desaturated below 94% with provision of supplemental oxygen (73% standard group). The eff ect of the inclusion of infants who were not aff ected by the study intervention is diffi cult to estimate, but on a population basis the eff ect was equivalent. Because children in the modifi ed group managed to a target of 90% had the same or better outcomes than did those managed to a 94% target, the WHO oxygen saturation target of 90% might not be the lower limit of tolerance for oxygen saturation in acute respiratory disease in children. Particularly in low-resource settings, the risk and benefi t balance of managing acute respiratory infection at a target lower than the current WHO recommended SpO₂ target could be considered. However, with increased risk of death shown for children with pneumonia and preterm infants with chronic lung disease managed at target oxygen saturation of lower than 90%, [28] [29] [30] the ethical boundaries to such a study would need careful consideration. 31, 32 Contributors SC devised the study concept, was chief investigator, and wrote the fi rst version of the manuscript, and with SL and EM devised the study protocol. SC, SCL, and EM, together with MM and FW, provided trial management. AR, IB, and SCL did the statistical analysis. EM and KAB did the economic analysis. TA, BE, JYP, KR, HT, SWT, CW, and JM were involved in design for study logistics and data collection. All authors contributed towards and approved the fi nal version of the manuscript.
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